<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03995147</url>
  </required_header>
  <id_info>
    <org_study_id>IRB19-0072</org_study_id>
    <nct_id>NCT03995147</nct_id>
  </id_info>
  <brief_title>Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma</brief_title>
  <official_title>Phase II Study of Pembrolizumab In Combination With R-CHOP for Patients With Untreated, High-Risk, Non-Germinal Center-Derived DLBCL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will research untreated non-germinal center diffuse large B cell lymphoma and what&#xD;
      causes the disease and the way patients respond to pembrolizumab combined with R-CHOP&#xD;
      chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2019</start_date>
  <completion_date type="Anticipated">August 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) rate when combining pembrolizumab with R-CHOP</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) rate after 6 cycles of pembrolizumab in combination with R-CHOP</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS) rate after 6 cycles of pembrolizumab in combination with R-CHOP</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) rate after 6 cycles of pembrolizumab in combination with R-CHOP</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment related adverse events as assessed by CTCAE v 4.0</measure>
    <time_frame>29 months</time_frame>
    <description>Safety and tolerability of pembrolizumab in combination with R-CHOP followed by Pembrolizumab.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>B Cell Lymphoma</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>High-grade B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks in combination with R-CHOP for 6 cycles.&#xD;
Participants that respond to the combination regiment will continue to receive pembrolizumab 200 mg IV every 3 weeks for additional 35 cycles (2 years).</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP Protocol</intervention_name>
    <description>R-CHOP chemo-immunotherapy will be administered in combination with Pembrolizumab</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male/female participants who are at least 18 years of age on the day of signing&#xD;
             informed consent with a histologically confirmed diagnosis of diffuse large B cell&#xD;
             lymphoma or high-grade B cell lymphoma of a non-germinal center phenotype according to&#xD;
             Hans criteria are eligible for enrollment in this study.&#xD;
&#xD;
          2. International Prognostic Index (IPI) score of ≥ 3, or an age-adjusted (aa) IPI score&#xD;
             of ≥ 2.&#xD;
&#xD;
          3. A male participant must agree to use a contraception during the treatment period and&#xD;
             for at least 120 days after the final dose of study treatment and refrain from&#xD;
             donating sperm during this period.&#xD;
&#xD;
          4. A female participant is eligible to participate if she is not pregnant, not&#xD;
             breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
               1. Not a woman of childbearing potential (WOCBP) OR&#xD;
&#xD;
               2. A WOCBP who agrees to follow the contraceptive guidance during the treatment&#xD;
                  period and for at least 120 days after the last dose of study treatment.&#xD;
&#xD;
          5. The participant (or legally acceptable representative if applicable) provides written&#xD;
             informed consent for the trial.&#xD;
&#xD;
          6. Have measurable disease with one or more measurable lymphoma lesions ( &gt;1.5 cm in the&#xD;
             long axis and &gt;1.0 cm in the short axis).&#xD;
&#xD;
          7. Patients must be able to provide an archived tumor tissue sample or newly obtained&#xD;
             core or excisional biopsy of a tumor lesion.&#xD;
&#xD;
          8. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
&#xD;
          9. Have adequate organ function. See below for adequate organ function laboratory values:&#xD;
&#xD;
               -  Hematological&#xD;
&#xD;
                    -  Absolute neutrophil count (ANC) less or equal to 1000/microliter&#xD;
&#xD;
                    -  Platelets less or equal to 100,000/microliters&#xD;
&#xD;
                    -  Hemoglobin less or equal to 8.0/grams per decilitre&#xD;
&#xD;
               -  Renal&#xD;
&#xD;
                    -  Creatinine or Measured/calculated creatinine clearance (CrCl) greater or&#xD;
                       equal to 1.5xULN or less than or equal to 30 mililiter per minute for&#xD;
                       participants with creatinine levels less than 1.5xULN&#xD;
&#xD;
               -  Hepatic&#xD;
&#xD;
                    -  Total bilirubin greater than or equal to 1.5 x ULN or direct bilirubin&#xD;
                       greater than or equal to ULN for participants with total bilirubin levels&#xD;
                       less than 1.5 x ULN&#xD;
&#xD;
                    -  AST (SGOT) and ALT (SGPT) greater than or equal to 2.5 x ULN (greater than&#xD;
                       or equal to 2.5 x ULN for participants with liver involvement)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive urine pregnancy test within 72 hours prior to the initiation of study&#xD;
             treatment. If the urine test is positive or cannot be confirmed as negative, a serum&#xD;
             pregnancy test will be required.&#xD;
&#xD;
          2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with&#xD;
             an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4,&#xD;
             OX-40, CD137).&#xD;
&#xD;
          3. Has received prior anti-lymphoma therapy, including radiation therapy, chemotherapy,&#xD;
             targeted therapy, or immunotherapy.&#xD;
&#xD;
             Note: Prior corticosteroid treatment (&lt;10 days in duration) to alleviate&#xD;
             lymphoma-elated symptoms is permitted.&#xD;
&#xD;
             Note: If participant received major surgery, he or she must have recovered adequately&#xD;
             from complications from the intervention prior to starting study treatment.&#xD;
&#xD;
          4. Has received a live vaccine within 30 days prior to the first dose of study drug.&#xD;
             Examples of live vaccines include, but are not limited to, the following: measles,&#xD;
             mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus&#xD;
             Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection&#xD;
             are generally killed virus vaccines and are allowed; however, intranasal influenza&#xD;
             vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.&#xD;
&#xD;
          5. Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks prior to the first dose of&#xD;
             study treatment.&#xD;
&#xD;
          6. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             (in dosing exceeding 10 mg daily of prednisone equivalent, with the exception of&#xD;
             short-term corticosteroid use to control lymphoma-related symptoms as outlined above)&#xD;
             or any other form of immunosuppressive therapy within 7 days prior to the first dose&#xD;
             of study drug.&#xD;
&#xD;
          7. Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 2 years. Note: Participants with basal cell carcinoma of the skin,&#xD;
             squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma,&#xD;
             cervical cancer in situ) that have undergone potentially curative therapy are not&#xD;
             excluded. Other exceptions may be permitted after discussion with the principal&#xD;
             investigator.&#xD;
&#xD;
          8. Has known active CNS involvement by lymphoma.&#xD;
&#xD;
          9. Has a diagnosis of high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 gene&#xD;
             rearrangements (double hit lymphoma), primary mediastinal lymphoma, gray zone&#xD;
             lymphoma, composite lymphoma, or previously-untreated low-grade lymphoma with disease&#xD;
             transformation to DLBCL.&#xD;
&#xD;
         10. Has severe hypersensitivity (≥ grade 3) to pembrolizumab and/or any of its excipients.&#xD;
&#xD;
         11. Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
         12. Has a history of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis.&#xD;
&#xD;
         13. Has an active infection requiring systemic therapy.&#xD;
&#xD;
         14. Has a known history of Human Immunodeficiency Virus (HIV) infection.&#xD;
&#xD;
         15. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]&#xD;
             reactive, Hepatitis B core [HBc] antibody total reactive, or HBV virus detected) or&#xD;
             known active Hepatitis C virus infection (defined as HCV RNA is detected). Note: All&#xD;
             patients will be screened for prior Hepatitis B exposure prior to starting therapy.&#xD;
             Hepatitis C testing is not required.&#xD;
&#xD;
         16. Has a known history of, or active infection with tuberculosis.&#xD;
&#xD;
         17. Has a history of solid organ transplantation.&#xD;
&#xD;
         18. Has a left ventricular ejection fraction &lt; 45%, myocardial infarction within 6 months&#xD;
             of initiating study treatment, New York Heart Assocation class III/IV heart failure,&#xD;
             or any uncontrolled cardiovascular conditions.&#xD;
&#xD;
         19. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the study, interfere with the subject's&#xD;
             participation for the full duration of the study, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
         20. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         21. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the study, starting with the screening visit through 120 days&#xD;
             after the last dose of trial treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin Kline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justin Kline, MD</last_name>
    <phone>773-702-5550</phone>
    <email>jkline@medicine.bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Kline, MD</last_name>
      <phone>773-702-5550</phone>
      <email>jkline@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Justin Kline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

